Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal methotrexate for non-infectious uveitis and uveitic macular oedema
ACTRN12610001004055Phase 2Completed
- Sponsor
- The Royal Victorian Eye and Ear Hospital
- Start
- Nov 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate in noninfectious uveitis (NIU) and cystoid macular edema (CME), sponsored by The Royal Victorian Eye and Ear Hospital. Primary endpoint: Best corrected Snellen visual acuity. Started Nov 2009; status: completed.
02
Drugs
methotrexate
03
Conditions
noninfectious uveitis (NIU)cystoid macular edema (CME)
Beyond the preview
Go deeper on ACTRN12610001004055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610001004055.